S
Stephen G. Ellis
Researcher at Cleveland Clinic
Publications - 668
Citations - 67828
Stephen G. Ellis is an academic researcher from Cleveland Clinic. The author has contributed to research in topics: Myocardial infarction & Percutaneous coronary intervention. The author has an hindex of 127, co-authored 655 publications receiving 65073 citations. Previous affiliations of Stephen G. Ellis include Scripps Health & Brown University.
Papers
More filters
Journal ArticleDOI
Unprotected Left Main Coronary Artery Disease: Management in the Post NOBLE and EXCEL Era.
TL;DR: In non-diabetic patients with low complexity coronary disease (SYNTAX score ≤32), PCI appears to be a reasonable alternative to CABG, especially for ostial and midshaft left main coronary lesions.
Journal Article
Subgroup Analysis From the RE-DUAL PCI Trial : Dual Antithrombotic Therapy With Dabigatran in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention
Jonas Oldgren,Philippe-Gabriel Steg,Stefan H. Hohnloser,Gregory Y.H. Lip,Stephen G. Ellis,Takeshi Kimura,Matias Nordaby,Jurriën M. ten Berg,Deepak L. Bhatt,Christopher P. Cannon,Eva Kleine +10 more
TL;DR: Subgroup Analysis From the RE-DUAL PCI Trial : Dual Antithrombotic Therapy With Dabigatran in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention finds that patients with atrial fibrillation undergoing percutaneous intervention are more likely to benefit from this therapy than those who receive chemotherapy.
Journal Article
Benchmarking cardiac catheterization laboratories: the impact of patient age, gender and risk factors on variable costs, device costs, total time and procedural time in 53 catheterization laboratories.
Edmund R. Becker,David Cohen,Steven D. Culler,Stephen G. Ellis,L M Green,R N Schnitzler,April W. Simon,William S. Weintraub +7 more
TL;DR: This study benchmarks cost and time data on 82,548 consecutive patient encounters in 53 CCLs for the 18-month period of January 1997 through June 1998, using data compiled from the OEP program, a relational database developed by Boston Scientific/Scimed for use inCCLs.
Journal ArticleDOI
Phase 1 study of pegargiminase combined with cisplatin and pemetrexed in patients with ASS1-deficient uveal melanoma.
Pui Ying Chan,Melissa Phillips,Ramsay Khadeir,Stephen G. Ellis,Jim Thomson,Amanda Johnston,Xiaoxing Feng,Bor-Wen Wu,John S. Bomalaski,Michael Sheaff,Peter W. Szlosarek +10 more
TL;DR: A phase 1 dose-escalation study of ASS1-deficient thoracic cancer patients with prior arginine deprivation therapy shows positive results for ASS1 loss, which is a biomarker to select for tumors sensitive to argininesuccinate deprivation therapy.